Trial Profile

Dose optimization study of LB1148

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tranexamic acid (Primary)
Indications Cardiogenic shock; Post-surgical adhesions; Postoperative ileus; Septic shock
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

05 Jul 2023 Status changed from recruiting to active, no longer recruiting, according to a Palisade Bio media release.
24 May 2023 According to a Palisade Bio media release, eight patients have been dosed in this study. The company remain on track to have that topline data from this study in the third quarter of this year.
11 May 2023 According to a Palisade Bio media release, first patient has been dosed in this study and the company expects to complete enrollment in Q3 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com